By Kelly Cloonan
Shares of Ocular Therapeutix fell after the company's first-quarter earnings and revenue missed Wall Street's expectations and its research-and-development expenses doubled.
The stock fell 11% to $7.87 on Monday. Shares have risen 28% in the past 12 months.
The company on Monday posted a loss of $64.1 million, or 38 cents a share, compared with $64.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 29 cents a share.
Revenue fell 28% to $10.7 million. Analysts expected $17 million.
The company's research-and-development expenses more than doubled to $42.9 million, up from $20.7 million in the same period a year earlier.
The increase reflects higher overall clinical expenses associated with its SOL-1 and SOL-R Phase 3 trials, as well as additional personnel and professional services to support the trials, the company said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 05, 2025 11:50 ET (15:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.